References

- ¹ Dent, C E, *British Medical Journal*, 1969, 2, 1419.
- ² Berry, E M, *et al*, *British Medical Journal*, 1973, 4, 640.
- ³ Payne, R B, *et al*, *British Medical Journal*, 1973, 4, 643.
- ⁴ Marshall, R W, and Nordin, B E C, *British Medical Journal*, 1974, 2, 729.
- ⁵ Parfitt, A M, *British Medical Journal*, 1974, 1, 520.
- ⁶ Prior, M, and Peake, M, *Australian Journal of Medical Technology*, 1975, 6, 5.
- ⁷ Pedersen, K O, *Scandinavian Journal of Clinical and Laboratory Investigation*, 1972, 30, 321.
- ⁸ Payne, R B, *Lancet*, 1973, 2, 375.
- ⁹ Berry, E M, *et al*, *British Medical Journal*, 1974, 2, 53.
- ¹⁰ Hodgkinson, H M, *British Medical Journal*, 1974, 2, 223.
- ¹¹ Payne, R B, *et al*, *British Medical Journal*, 1974, 1, 393.
- ¹² Payne, R B, *et al*, *British Medical Journal*, 1974, 2, 504.
- ¹³ Payne, R B, *et al*, *British Medical Journal*, 1974, 3, 345.
- ¹⁴ Christiansen, C, *et al*, *Clinica Chimica Acta*, 1975, 62, 65.
- ¹⁵ Husdan, H, *et al*, *Clinical Chemistry*, 1974, 20, 529.
- ¹⁶ van Leeuwen, A M, Thomasse, C M, and Kapteyn, P C, *Clinica Chimica Acta*, 1961, 6, 550.

Effect on adrenal function of topically applied clobetasol propionate (Dermovate)

C F ALLENBY, R A MAIN, R A MARSDEN, C G SPARKES

British Medical Journal, 1975, 4, 619-621

Summary

Thirty-nine patients (15 outpatients and 24 inpatients) with a variety of skin diseases affecting variable areas of the body surface were treated with clobetasol propionate ointment (Dermovate). Before and after treatment the adrenal response to an intramuscular injection of tetracosactrin was tested and additional 9 am plasma cortisol levels were measured at intervals during treatment. A satisfactory initial therapeutic response was achieved in almost all cases during the trial period. When more than 50 g of ointment a week was used a significant number of patients developed adrenal suppression. When less than 50 g per week was used any suppression tended to be transient, and cortisol levels recovered as treatment progressed.

Introduction

It is well recognised that when corticosteroids are applied to the skin there may be sufficient percutaneous absorption to affect hypothalamic-pituitary-adrenal (HPA) function. This effect seems to parallel topical anti-inflammatory activity and is more likely to occur when large quantities of cream or ointment are applied to extensive areas of diseased skin.

Clobetasol propionate in a strength of 0.05% (Dermovate) is a highly effective corticosteroid preparation.¹ Walker *et al* have shown that it has little effect on the HPA axis of outpatients when applied topically.² They assessed adrenal function by estimating plasma cortisol levels at the beginning and end of treatment. But cortisol values during the early treatment period, when maximum absorption is most likely, were not measured. Furthermore, inpatients, whose lesions are usually more extensive, require larger amounts of steroid preparation than

outpatients. For these reasons we investigated the effects of treatment with clobetasol propionate in both inpatients and outpatients.

Patients and methods

Twenty-three patients with psoriasis, 15 with dermatitis, and one with lichen planus were included. Children and patients who had received systemic steroid treatment during the previous six months were excluded. Ointment was applied to lesions up to twice daily without the use of occlusion (except in case 11). At the end of treatment the amount of ointment used was calculated.

HPA function in all patients was investigated using the short tetracosactrin test described by Wood *et al*,³ and 9 am plasma cortisol levels were assessed. Cortisol levels were considered abnormal if they were below 166 nmol/l (6 µg/100 ml). An abnormal response to an injection of 250 µg of tetracosactrin was recorded if after 30 minutes plasma cortisol levels had not risen by at least 193 nmol/l (7 µg/100 ml) to a level of 552 nmol/l (20 µg/100 ml) or more. Plasma cortisol estimations were carried out in the same laboratory using a fluorimetric method described by Spencer-Peet *et al*.⁴

The extent of the disease was graded as follows: grade 1, small circumscribed lesions—for example, on elbows, knees, and scalp; grade 2, under 50% of body surface affected; grade 3, over 50% of body surface affected; grade 4, almost confluent lesions.

Results

The results are given in table I. The ages of the 39 patients ranged from 15 to 79 years (median 48 years). There were 19 women and 20 men. Fifteen were treated as outpatients and 24 were inpatients. In most cases about half of the skin surface was treated. Only one patient (case 12) failed to improve. During treatment two patients developed an acneform rash.

ADRENAL FUNCTION

Adrenal function remained normal throughout the trial in only 14 patients (10 outpatients and 4 inpatients). Nineteen patients with initial normal 9 am plasma cortisol levels had abnormal levels for a variable period during treatment. In seven of these the plasma cortisol levels recovered, and in six of the seven the final tetracosactrin test was also normal. Of the 12 patients with depressed cortisol levels at the end of the trial half had an abnormal response to tetracosactrin.

Eight patients had a poor response to tetracosactrin at the beginning of the trial, and in four the 9 am plasma cortisol level was also abnormal. Evidence of improving adrenal function was present in three patients at the end of the trial (cases 17, 18, and 34). These eight patients had probably used large amounts of topical corticosteroids before starting the trial.

Department of Dermatology, Lister Hospital, Hertfordshire
C F ALLENBY, MB, MRCP, consultant dermatologist

Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen
R A MAIN, MB, FRCP, consultant dermatologist and honorary senior lecturer

R A MARSDEN, MB, MRCP, registrar in dermatology (present address: Slade Hospital, Headington, Oxford)

Clinical Research Unit, Glaxo Laboratories Ltd, Greenford, Middlesex

C G SPARKES, BSC, PHD, clinical pharmacologist

TABLE I—Clinical details and cortisol levels in outpatients (cases 1-15) and inpatients (cases 16-39)

Case No	Disease	Extent of disease (grade)	Clinical result	Quantity of ointment used (g/week)	Plasma cortisol (nmol/l)					
					Day 0		Values on other days (day given in parentheses)	Final day		
					9 am	30 min after tetracosactrin		Day	9 am	30 min after tetracosactrin
1	Psoriasis	1	Improved	23	312	933		27	373	1087
2	Acute dermatitis	1	Healed	18	353	875		27	248	869
3	Dermatitis	1	Improved	30	298	624		10	582	947
4	Psoriasis	2	Improved	29	618	952		18	466	745
5	Psoriasis	2	Improved	26	342	698		24	400	828
6	Psoriasis	2	Healed	25	367	599	(10) 77, (18) 30	31	257	673
7	Psoriasis	2	Improved	37	464	999		14	491	850
8	Psoriasis	2	Improved	125	315	817		7	110	331*
9	Psoriasis	2	Improved	100	342	817		14	353	696
10	Psoriasis	2	Improved	87	414	745		14	14	196*
11	Dermatitis	2	Improved	16	635	878		13	751	905
12	Atopic dermatitis	2	Static	41	414	773		14	290	781
13	Psoriasis	2	Improved	72	707	839		14	718	759
14	Psoriasis	3	Improved	78	552	662*		14	284	425*
15	Dermatitis	4	Healed	159	356	662		7	55	168*
16	Dermatitis	1-2	Healed	70	483	878	(4) 135	8	88	348*
17	Psoriasis	2	Healed	23	502	607*	(8) 55, (15) 30, (17) 119	36	326	696
18	Psoriasis	2	Healed	39	149	403*	(8) 108, (16) 119	18	179	546
19	Psoriasis	2	Healed	48	497	745	(6) 364, (17) 480	22	508	762
20	Lichen simplex	2	Improved	44	215	914	(2) 287, (5) 130	8	276	580
21	Psoriasis	2	Improved	50	284		(3) 108, (5) 108, (6) 97	7	160	392*
22	Nummular dermatitis	2	Improved	25	444		(4) 226, (5) 251, (6) 193	8	505	304*
23	Dermatitis	2	Healed	131	39	356*	(1) 63	7	23	229
24	Psoriasis	3	Healed	43	505	867	(8) 69, (15) 61, (17) 342	36	273	665
25	Psoriasis	3	Almost Healed	75	420	696	(5) 86, (7) 80	19	141	199*
26	Psoriasis	3	Improved	75	422	740	(2) 116	21	284	693
27	Psoriasis	3	Healed	82	378	629	(1) 55, (4) 69, (6) 14, (8) 69	9	353	489*
28	Dermatitis	2	Healed	70	524	828	(1) 83, (3) 97, (4) 69, (6) 179	7	28	392*
29	Psoriasis	3	Improved	110	373	745	(1) 52, (4) 0, (6) 0, (8) 14, (12) 0	14	28	141*
30	Dermatitis	3	Improved	125	643	941	(2) 284, (3) 403, (5) 284, (7) 268, (9) 304	10	273	682
31	Psoriasis	3	Improved	142	268	789	(1) 309, (4) 295	8	94	284*
32	Psoriasis	3	Improved	141	500	781		8	279	707
33	Neuro-dermatitis	3	Improved	175	287	891		8	213	635
34	Annular lichen planus	3	Improved	208	127	489*	(1) 80, (2) 121, (3) 119, (4) 163, (6) 282	8	496	726
35	Psoriasis	3	Improved	236	806	969*	(2) 75, (5) 44	8	58	251*
36	Psoriasis	3	Healed	268	61	505*	(1) 61, (3) 0, (4) 0, (5) 17, (6) 77, (7) 47, (10) 77, (11) 30, (12) 47	13	28	144*
37	Dermatitis	4	Healed	159	334	784	(6) 91	7	63	386*
38	Dermatitis	4	Healed	173	687	999	(1) 94, (4) 149, (5) 508	6	358	566
39	Exfoliative dermatitis	4	Healed	175	406	502*	(2) 113, (4) 38, (6) 14, (7) 41	8	41	199*

*Tetracosactrin test result was abnormal.

Conversion: SI to traditional units—Cortisol: 1 nmol/l $\approx$ 0.036 μ g/100 ml.

TABLE II—Plasma cortisol levels in relation to quantity of clobetasol propionate ointment used

Quantity of ointment used (g/week)	No of patients	No of patients with normal plasma cortisol throughout treatment	No of patients with normal plasma cortisol at end of treatment but showing earlier lowering	No of patients with low plasma cortisol at end of treatment
<i>Outpatients</i>				
<50	9	8	1	0
>50	6	2	0	3
<i>Inpatients</i>				
<50	6	1	4	0
>50	18	3	4	11

In case 22 cortisol levels fell only moderately during treatment. The level in this patient on the last day (505 nmol/l) suggested that the value of plasma cortisol (304 nmol/l) after tetracosactrin was wrong. Two patients were not tested with tetracosactrin before treatment (cases 21 and 22) but their 9 am cortisol levels were normal and the tetracosactrin test would probably also have been normal. Two patients (cases 11 and 13) did not show a normal rise in plasma cortisol after tetracosactrin but they were considered to be normal since their initial levels were high and a reasonable response was recorded.

QUANTITY OF OINTMENT USED

The results indicated that there was a relation between the amount

of ointment used per week and plasma cortisol levels (table II). Most inpatients were using large quantities of ointment: only six of the 24 inpatients were using less than 50 g a week and all had normal cortisol levels at the end of treatment, with five having a normal response to tetracosactrin. Four of the six had reduced 9 am plasma cortisol levels, however, at some earlier stage of treatment. The 11 inpatients whose plasma cortisol levels were low at the end of treatment were all using more than 50 g per week. Nine of the 15 outpatients, on the other hand, were using less than 50 g a week, and again all had normal plasma cortisol levels with normal responses to tetracosactrin at the end of the treatment. The three outpatients with low plasma cortisol levels at the end of treatment were all using more than 50 g a week.

Those patients with the most extensive skin disease tended to use the most ointment.

DURATION OF TREATMENT

Eleven of the 15 outpatients were treated for 14 days or more compared with seven of the 24 inpatients.

Multiple 9 am plasma cortisol level estimations in inpatients showed that levels tended to slowly increase during treatment in about half the patients. The effect was not usually seen in patients using large quantities of ointment.

Discussion

The results show that if over 50 g of clobetasol propionate ointment is applied per week then adrenal suppression may occur.

This is not surprising since suppression of HPA function in patients using topical steroid preparations is well recorded. James *et al*⁵ found that betamethasone valerate caused lowering of plasma cortisol levels when used with occlusion in inpatients. The same effect has been shown from triamcinolone acetonide without occlusion.⁶ Feiwei *et al*⁷ have shown that plasma cortisol levels in children treated as outpatients with betamethasone valerate tend to be low, although this is not so apparent with adults. Growth retardation, oedema, and Cushingoid features have been noted in babies and children receiving topical corticosteroids.⁸⁻¹⁰

Clobetasol propionate is a highly effective topical corticosteroid preparation.¹¹ A six-month study comparing clobetasol propionate and fluocinolone acetonide in the treatment of psoriasis indicates that it may be even more effective than was shown by earlier short-term trials.¹² It is reasonable to expect that the topical activity of a steroid is correlated with its ability to produce systemic effects, and this has been shown using animal models.¹³

Recent evidence suggests that prolonged application of a topical steroid in adult outpatients may not produce significant adrenal suppression. Wilson *et al*¹⁴ studied plasma cortisol levels in 295 outpatients, 90% of whom were using betamethasone valerate, and concluded that only a few patients so treated would have abnormal HPA function. The use of the insulin stress test in Wilson *et al*'s study and in our outpatient group might have shown abnormal HPA function not shown by simpler methods of assessment. Nevertheless, Munro and Clift¹⁵ used this more rigorous test in studying 40 outpatients comparable with those studied by Wilson *et al*¹⁴ and concluded that there was little effect on adrenal function.

Our results show that when less than 50 g of clobetasol propionate ointment a week is used there may be transient suppression of HPA function, which apparently recovers as the skin heals. This is probably because less ointment is applied and the epidermal barrier is restored, thereby reducing corticosteroid absorption.⁶⁻¹⁶ These observations may explain the results of Walker *et al*,² who found that clobetasol propionate had little effect on plasma cortisol levels. In most of their

patients 5% or less of the body surface area was diseased, and the patients used less than 50 g of ointment a week. It is also conceivable that the timing of their samples—at 14 and 28 days of treatment—allowed any early adrenal suppression to recover despite continuing treatment. This might also account for the apparent lack of systemic activity reported in the other studies cited.

When more than 50 g of clobetasol propionate ointment a week is being used clinicians should be aware of the possibility of adrenal suppression. In children these effects will probably occur with smaller quantities. While short-term adrenal suppression is probably of little clinical significance, long-term suppression should be prevented. Consequently, the most desirable method of using clobetasol propionate in many cases may be to give short intensive courses to induce rapid healing. The systemic and local side effects described by Staughton and August¹⁷ would then be avoided.

References

- 1 Sparkes, C G, and Wilson, L, *British Journal of Dermatology*, 1974, **90**, 197.
- 2 Walker, S R, *et al*, *British Journal of Dermatology*, 1974, **91**, 339.
- 3 Wood, J B, *et al*, *Lancet*, 1965, **1**, 243.
- 4 Spencer-Peet, J, Daly, J R, and Smith, V, *Journal of Endocrinology*, 1965, **31**, 235.
- 5 James, V H T, Munro, D D, and Feiwei, M, *Lancet*, 1967, **2**, 1059.
- 6 Keczes, K, *et al*, *British Journal of Dermatology*, 1967, **79**, 475.
- 7 Feiwei, M, James, V H T, and Barnet, E S, *Lancet*, 1969, **1**, 485.
- 8 Benson, P F, and Pharaoh, P O D, *Guy's Hospital Reports*, 1960, **109**, 212.
- 9 Feinblatt, B I, *et al*, *American Journal of Diseases of Children*, 1966, **112**, 218.
- 10 Keipert, J A, and Kelly, R, *Medical Journal of Australia*, 1971, **1**, 542.
- 11 Woodbridge, P, *Practitioner*, 1974, **212**, 732.
- 12 Floden, C H, *et al*, to be published.
- 13 Child, K J, *et al*, *Archives of Dermatology*, 1968, **97**, 407.
- 14 Wilson, L, Williams, D I, and Marsh, S D, *British Journal of Dermatology*, 1972, **88**, 375.
- 15 Munro, D D, and Clift, D C, *British Journal of Dermatology*, 1973, **88**, 381.
- 16 Scoggins, R B, and Kliman, B, *New England Journal of Medicine*, 1965, **273**, 831.
- 17 Staughton, R C D, and August, P J, *British Medical Journal*, 1975, **2**, 419.

PRELIMINARY COMMUNICATION

The monocystic ovary syndrome

J W DELAHUNT, R V CLEMENTS, I D RAMSAY,
J NEWTON, W P COLLINS, J LANDON

British Medical Journal, 1975, **4**, 621-622

Summary

Three patients with oligomenorrhoea and hirsutism thought to have the polycystic ovary syndrome were

North Middlesex Hospital, London N18 1QX

J W DELAHUNT, MRCP, MRACP, research fellow

R V CLEMENTS, FRCS, MRCOG, consultant obstetrician and gynaecologist

I D RAMSAY, MD, MRCP, consultant physician, Regional Endocrine Centre

King's College Hospital Medical School, London SE5

J NEWTON, MD, MRCOG, senior lecturer in obstetrics and gynaecology

W P COLLINS, DSC, FRIC, senior lecturer in biochemistry

St Bartholomew's Hospital, London EC1

J LANDON, MRCP, MRCS, professor of chemical pathology

found to have only one ovarian cyst. Endocrine findings were similar to those found in the polycystic syndrome, but apart from the single cyst the ovaries were histologically normal; a biopsy specimen of a cyst showed normal follicular appearances and no evidence of luteinisation. These cysts may be the cause of this condition, producing abnormal amounts of ovarian steroids which modify the pituitary response. Further studies are needed, however, to determine this possibility.

Introduction

The syndrome of oligomenorrhoea and hirsutism with polycystic changes in the ovaries has been recognised for many years,^{1 2} although in some cases no obvious ovarian changes are apparent.^{2 3} We report here, for the first time, three cases in which the only ovarian abnormality was a single, and possibly functional, cyst.

Patients and methods

The cases were selected from a study of patients likely to have the polycystic ovary syndrome. Hirsutism was estimated by a method on which 96% of a female outpatient population scored seven or below.⁴ No patient had clinical or biochemical evidence of thyroid, adrenal,